

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Peijia Medical Limited**

### **沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

## **VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY THE CHAIRMAN AND THE SENIOR MANAGEMENT**

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that on January 19, 2024 and January 22, 2024, Dr. Yi Zhang (“**Dr. Zhang**”) (the chairman of the Board and an executive Director) and the Company’s senior management (the “**Senior Management**”) acquired certain shares of the Company (the “**Shares**”) from the market at a total consideration of HK\$768,000 (the “**Shareholding Increase**”) using their own funds.

As informed by Dr. Zhang and the Senior Management, the Shareholding Increase was based on their confidence towards the research and development of the Company’s pipeline product, and do not rule out any further acquisition of the Shares as and when appropriate in accordance with the laws and regulations.

According to the information available to the Company and so far as the Directors are aware, the Company has maintained sufficient public float of the Shares in issue upon completion of the Shareholding Increase and as at the date of this announcement.

By order of the Board  
**Peijia Medical Limited**  
**Dr. Yi Zhang**  
*Chairman and Executive Director*

Hong Kong, January 22, 2024

*As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip, and Mr. Huacheng Wei as independent non-executive Directors.*